Pine Valley Investments Ltd Liability Co Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Pine Valley Investments Ltd Liability Co increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 59.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,679 shares of the medical device company’s stock after acquiring an additional 2,111 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in DexCom were worth $381,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Blue Whale Capital LLP boosted its stake in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC increased its position in DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new position in DexCom in the 3rd quarter valued at about $683,000. National Pension Service lifted its holdings in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of DexCom during the 3rd quarter worth about $650,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DXCM. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Stock Down 2.2 %

DXCM opened at $77.19 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a 50 day moving average price of $73.58 and a 200 day moving average price of $84.99. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market cap of $30.15 billion, a PE ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.